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Neuropeptides exert essential functions in animal physiology by controlling e.g.,
reproduction, development, growth, energy homeostasis, cardiovascular activity and
stress response. Thus, identification of neuropeptides has been a very active field of
research over the last decades. This review article presents the various methods used
to discover novel bioactive peptides in vertebrates. Initially identified on the basis of their
biological activity, some neuropeptides have also been discovered for their ability to
bind/activate a specific receptor or based on their biochemical characteristics such as
C-terminal amidation which concerns half of the known neuropeptides. More recently,
sequencing of the genome of many representative species has facilitated peptidomic
approaches using mass spectrometry and in silico screening of genomic libraries.
Through these different approaches, more than a hundred of bioactive neuropeptides
have already been identified in vertebrates. Nevertheless, researchers continue to find
new neuropeptides or to identify novel functions of neuropeptides that had not been
detected previously, as it was recently the case for nociceptin.
Keywords: neuropeptide, identification, peptidomic approach, de novo, bioactiity, review
CHARACTERISTICS OF NEUROPEPTIDES
More than one hundred bioactive neuropeptides have been identified in vertebrates, varying
in length from 3 amino acids, for thyrotropin-releasing hormone (TRH), up to several dozens
of amino acids (82 for nesfatin-1). All neuropeptides are generated by cleavage of precursors
of higher molecular weight that belong to three categories (Figure 1; Douglass et al., 1984).
The first category includes mono-functional precursors that give rise to only one bioactive
peptide flanked by one or two sequences called cryptic peptides, the function of which is
generally unknown. Within these precursors, the bioactive peptide may be located at the
N-terminal extremity upstream of the cryptic peptide as for neuropeptide Y (Cerdá-Reverter
et al., 2000), in an intermediate position as for cholecystokinin (Beinfeld, 1997) or at the
C-terminal extremity as for somatostatin and urotensin II (Vaudry et al., 2015; Figure 1A).
The second category consists of mono-functional precursors with several copies of the bioactive
peptide such as TRH, which exists in 5 copies within the same precursor in rat (Lee
et al., 1988), resulting most likely from intragenic duplications during evolution (Figure 1B).
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FIGURE 1 | Examples illustrating the 3 categories of neuropeptide precursors. (A) Illustration of monofonctional precursors with single copy of the peptide of interest
as it is the case for CCK, UII, NPY, and SST. (B) Illustration of monofonctional precursors with several copies of the peptide of interest as it is the case for TRH. (C)
Illustration of multifonctional precursors which express several different bioactive peptides as it is the case with POMC. ACTH: adrenocorticotropic hormone. CCK:
cholecystokinin. POMC: pro-opiomelanocortin. CLIP: corticotropin-like intermediate lobe peptide. LPH: lipotropic hormone. MSH: melanocyte-stimulating hormone.
NPY: neuropeptide Y. SP: signal peptide. SST: somatostatin. TRH: thyrotropin-releasing hormone. UII: urotensin II. aa: aminoacid. Adapted from Neveu (2012).
The third category corresponds to multifunctional precursors
giving rise to distinct bioactive peptides, the archetype being pro-
opiomelanocortin (POMC), the precursor of adrenocorticotropic
hormone (ACTH), melanotropic hormones (α-, β- and γ-MSH)
and β-endorphin (Figure 1C; Nakanishi et al., 1979). The
precursors of the first category can eventually be reclassified in
the third category if an activity for one of the cryptic peptides is
discovered (Figures 1A,C). In fact, sequences initially considered
cryptic may sometimes prove to have a biological effect, as it
was the case for nocistatin, present in the same precursor as
nociceptin and having an inverse effect on pain transmission
(Okuda-Ashitaka and Ito, 2000).
The precursor polypeptide chains of neuropeptides exhibit
several common structural features. First, a signal peptide
consisting of a hydrophobic sequence of about twenty amino
acids is located at the N-terminal extremity of the precursor.
This signal peptide allows the translocation of the polypeptide
into the lumen of the endoplasmic reticulum (Coleman et al.,
1985). Once the signal peptide is translated by the ribosome, the
complex binds to a ribonucleoprotein associated with an RNA
molecule, the signal recognition particle (Figure 2). This particle
then binds to its receptor located on the reticulum membrane,
allowing the elongation and translocation of the preprohormone
polypeptide into the reticulum to continue (Walter et al., 1984).
During translation, the signal peptide is cleaved off by an
endopeptidase, the signal peptidase.
Precursors translocated in the lumen of the reticulum and
subsequently transported in cell compartments of the secretory
pathway, undergo various post-translational modifications, such
as the formation of a disulfide bridge between two cysteines,
phosphorylation of a serine or threonine residue, tyrosine
sulfation, octanoylation, C-terminal amidation, and N-terminal
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FIGURE 2 | Neuropeptide biosynthesis. The signal recognition particle (SRP) is fixed to the complex formed by the peptide, the ribosome and the mRNA (¶) and
then binds to its receptor on the endoplasmic reticulum membrane (·). This allows the peptide to enter the reticulum through the translocon so that peptide
synthesis can continue (¸). The signal peptide (red circles) is then cleaved off by an endopeptidase (¹). Once synthesized, the neuropeptide will pass through the
Golgi apparatus to undergo post-translational modifications (º) before being secreted in a regulated manner (»).
acetylation or pyroglutamylation. Each of these modifications
can strongly affect the activity of the peptide and/or its
resistance to enzymatic degradation. For example, sulfation of
tyrosine in position 2 of cholecystokinin (Gigoux et al., 1998),
N-octanoylation of the third serine residue of ghrelin (Kojima
et al., 1999; Muccioli et al., 2001) or acetylation of the N-terminal
serine of α-MSH (O’Donohue et al., 1981) significantly increases
the affinity of these peptides for their receptors. Similarly,
the presence of a disulfide bridge contributes to the spatial
conformation of peptides, and its reduction usually leads to
their inactivation as for oxytocin and urotensin II (Meraldi
et al., 1977; Labarrère et al., 2003). These chemical modifications
take place either during the transit of the precursor from the
reticulum to the Golgi apparatus, or in the secretory vesicles.
For example, disulfide bonds are formed in the endoplasmic
reticulum, sulfation occurs in the Golgi apparatus and amidation,
which concerns more than half of the neuropeptides, takes place
in the secretory granules (Figure 2).
Once the precursors reach the trans-Golgi or secretory
granules, they undergo specific cleavage by endoproteases called
prohormone convertases (PCs) to give rise to biologically active
peptides. There are 7 PCs in mammals: PC2 (Smeekens and
Steiner, 1990), furin (van de Ven et al., 1990), PC1/3 (Seidah
et al., 1991), PACE4 (Kiefer et al., 1991), PC4 (Nakayama
et al., 1992), PC5/6 (Lusson et al., 1993) and PC7 (Tsuji
et al., 1994). These 7 PCs share an affinity for substrates
with basic amino acids (Fricker, 2012). The most common
cleavage patterns consist of two basic amino acids such as
a lysine-arginine and arginine-lysine doublets, two arginines
or two lysines. PC1/3 and PC2, the most abundant enzymes,
cleave the precursors downstream of these doublets and thus
leave the two basic amino acids at the C-terminal extremity
of the peptide. More rarely, the cleavage site may consist of
a single basic amino acid as is the case for somatostatin-28
and the octadecaneuropeptide ODN (Barbaccia et al., 1990;
Brakch et al., 1995). In the vast majority of cases, after cleavage,
the basic residues are removed by carboxypeptidases (Fricker
and Snyder, 1982; Song and Fricker, 1995), except for ODN
and cortistatin (Ferrero et al., 1986; de Lecea et al., 1996).
Two other PCs that do not cleave at basic sites have been
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characterized: subtilisin-kexin-isozyme (Seidah et al., 1999) and
proprotein convertase subtilisin-kexin isozyme (Seidah et al.,
2003). Differential expression of PCs depending on the cell
type leads to tissue-specific cleavages of the precursors. An
illustrative example of differential maturation is given by POMC
that generates distinct bioactive peptides according to the tissues.
Thus, in corticotrope cells of the adenohypophysis, where just
PC1/3 is present, only half of the 8 potential cleavage sites
are processed, giving rise to ACTH and β-LPH, whereas in
neurons of the arcuate nucleus and melanotrope cells of the
intermediate lobe of the pituitary, which express both PC1/3 and
PC2, the maturation is complete and leads to the formation of
α-MSH and β-endorphin (Bicknell, 2008). After cleavage and
post-translational modifications, the bioactive peptide(s) is (are)
stored in secretory vesicles which, upon depolarization of the cell,
merge with the plasma membrane to release their content in the
extracellular space.
Neuropeptides, therefore, represent a particular type of
intercellular signaling molecules. Indeed, they are produced by
nerve cells (and often by other cell types including endocrine
cells, skin cells. . .), they derive from the specific cleavage of
a preprohormone polypeptide harboring a signal peptide,
and they are secreted in a controlled manner. Once released
in the extracellular space, they act at low concentrations
by binding to specific receptors before being degraded
without reuptake, unlike neurotransmitters. These physical
and biological characteristics can be exploited to identify
novel neuropeptides. Since the first characterization of the
neuropeptides oxytocin and vasopressin (Du Vigneaud,
1954), many research teams have set out strategies to
discover novel neuropeptides. The techniques used for their
identification are diverse and have evolved considerably over the
last decades.
IDENTIFICATION FROM A BIOLOGICAL
ACTIVITY
The initial method employed to discover bioactive peptides relies
on a biological test, which consists of measuring the effect
of tissue extracts, most often brain extracts for neuropeptides,
on a physiological parameter. These extracts are then purified
until a single compound is isolated. Two types of approaches
can be distinguished for bioassays depending on whether the
activity being tested corresponds to the “main function” of the
peptide or to a mere pharmacological effect (Figure 3). Regarding
the main function, it is through this approach that the first
neuropeptide, oxytocin, was isolated by Du Vigneaud et al.
(1953). Hypothalamic hypophysiotropic neuropeptides such as
TRH, gonadotropin-releasing hormone and somatostatin have
been discovered via the same approach by studying the ability
of hypothalamic extracts to modulate the release of thyrotropin
(Burgus et al., 1969), luteinizing hormone, follicle-stimulating
hormone (Schally et al., 1971) and growth hormone (Brazeau
et al., 1973). A similar strategy was also used to identify pituitary
adenylate cyclase-activating polypeptide (PACAP) from a sheep
hypothalamic extract by measuring the activation of adenylate
FIGURE 3 | Schematic representation summarizing the various strategies of
identification of bioactive peptides. Examples of the peptides identified
through the various strategies are presented.
cyclase in pituitary cells, hence the name of this peptide (Miyata
et al., 1989; Figure 4).
Besides, pharmacological (non-specific) activity tests were
used to isolate other peptides such as substance P or enkephalins.
For instance, the purification of substance P was carried out
by measuring the effects of gut extracts, and later of brain
extracts, on the contraction of intestine smooth muscles (Euler
and Gaddum, 1931). However, it took four decades before the
sequence of the peptide was determined (Chang et al., 1971).
Regarding enkephalins, the test consisted in monitoring the
effect of brain extracts on electrically evoked contractions of the
mouse vas deferens and guinea pig ileum (Hughes et al., 1975).
These inhibitory effects were completely antagonized by the
opioid receptor antagonist naloxone.
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FIGURE 4 | Strategy of identification of pituitary adenylate cyclase-activating polypeptide (PACAP). The team of Akira Arimura extracted peptides from 5000 ovine
hypothalamic fragments and separated them according to their charge and hydrophobicity. A highly basic peptide different from any other known hypophysiotropic
neurohormone was found to activate cAMP in cultured rat anterior pituitary cells. Characterization revealed a 38-amino acid peptide with 68% identity with VIP that
they named pituitary adenylate cyclase-activating polypeptide or PACAP (Arimura, 2007). cAMP: cyclic adenosine monophosphate.
Even though these approaches by biological tests have led to
the identification of several neuropeptides, they are not devoid
of drawbacks. In particular, the successive steps of purification
and the activity tests until reaching a single bioactive compound
can be very long. Furthermore, once a peptide such as PACAP
has been characterized, decades of research are still necessary to
identify its numerous functions (Vaudry et al., 2000, 2009) and
decipher its mechanisms of action (Vaudry et al., 1998, 2002).
IDENTIFICATION FROM THE RECEPTOR
Large-scale cloning of G-protein coupled receptors (GPCRs),
has led to the identification of numerous so-called orphan
receptors, that is, receptors whose endogenous ligands have not
yet been identified. The human genome encompasses∼800 genes
encoding GPCRs of which 448 are sensory receptors (Mombaerts,
2004). Among the remaining ∼350 GPCRs, ∼140 still have no
identified ligand (Stockert and Devi, 2015). Since about 50% of
non-orphan GPCRs are activated by (neuro)peptides, a quick
extrapolation indicates that approximately 70 orphan GPCRs
should recognize one or several biologically active peptides(s) as
natural ligand(s) (Alexander et al., 2011). These peptide-binding
GPCRs thus represent very attractive targets for the identification
of novel neuropeptides through a reversed pharmacology
approach via the screening of tissue extracts or synthetic peptide
libraries. The search for the endogenous ligand(s) of an orphan
GPCR necessitates the stable or transient expression of the
receptor cDNA in a cell line in order to screen tissue extracts.
The pairing of a potential neuropeptide to a receptor of interest
can be carried out through two types of approaches (Figure 3).
The first one uses a labeled ligand (most often radioactive) whose
binding to the receptor is displaced by the endogenous ligand
(Figure 3). In this case, an already known neuropeptide is used
to identify novel related endogenous peptides that bind to the
same receptor. This approach allowed the identification of several
neuropeptides from prodynorphin, including different types of
dynorphins (Pert et al., 1977; Goldstein et al., 1979). The main
drawback of this technique is the requirement to label a peptidic
ligand by adding a radioactive iodine atom to a tyrosine without
dramatically altering its affinity. Alternatively, it is possible to
label peptides with tritiated or deuterated atoms which do not
impair the structure of the molecules (Allen et al., 1982). The
second method focuses on the receptor activation, studied by
measuring a physiological parameter such as cytosolic calcium
level, second messenger formation, acidification, . . . (Figure 3).
It is through this approach that nociceptin and orexin were
identified (Meunier et al., 1995; Reinscheid et al., 1995; Sakurai
et al., 1998). Variants of this approach include imaging techniques
that monitor e.g., the internalization of the fluorochrome-labeled
tagged receptor (De Mota et al., 2004) or microcalorimetry that
reflect the interaction between the receptor and its ligand through
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quantification of conformational change-induced temperature
variations (Jerabek-Willemsen et al., 2014).
IDENTIFICATION FROM BIOCHEMICAL
CHARACTERISTICS OF
NEUROPEPTIDES
The methods presented above focus on the discovery of
neuropeptides via their activity, either at the tissue or cell
level. Besides this functional-based strategy, it is possible to
identify novel neuropeptides according to their biochemical
features. The main characteristic signature is peptide amidation,
which can be studied by chemical precipitation steps of the
amidated fragments prior to their purification. This approach has
been used successfully by Viktor Mutt’s team to isolate various
neuropeptides, some of which had already been identified in
other species, such as cholecystokinin (Tatemoto et al., 1984),
while others were completely novel such as neuropeptide Y
(Tatemoto et al., 1982) and galanin (Tatemoto et al., 1983).
The main difficulty with this approach comes from the very
large amount of material required: it took for example 400 kg
of pig brain to purify and characterize neuropeptide Y. It
should be noted that the continuous improvement of analytical
instrument sensitivity can now greatly facilitate the identification
steps. However, only about half of the known neuropeptides
are amidated (Kim and Seong, 2001), implying that the other
half cannot be identified by this technique. Other biochemical
characteristics can be used to identify neuropeptides within
precursors, such as the presence of cleavage sites for PCs, which
has allowed to discover new peptides from precursors already
known as it was the case for nocistatin (Okuda-Ashitaka et al.,
1998). Finally, a method more rarely used is based on the
activity of the enzymes involved in peptide biosynthesis, such
as carboxypeptidase E (Hook and Loh, 1984). After cleavage of
the precursor by PCs, carboxypeptidase E acts to remove the
basic amino acids located at the C-terminal position. Inactivation
of carboxypeptidase E results in the accumulation of an almost
mature form of the putative neuropeptide that can then be
more easily purified and sequenced. Such a strategy led to the
identification of PEN peptides, derived from a precursor close
to the granins, SAAS (Fricker et al., 2000), whose receptor has
not yet been identified. This technique has the same limitations
as the previous ones, namely not all neuropeptides are substrates
of carboxypeptidase E. Moreover, it should be kept in mind that
all these approaches to identify neuropeptides are only the first
steps of a long research process since once the candidate has been
purified and sequenced, it is necessary to identify its receptor(s)
in order to investigate into details its functions.
IDENTIFICATION USING GENOMIC
APPROACHES
Comparison of cDNA or genomic sequences between distant
species has allowed the discovery, in mammals, of several
biologically active peptides previously identified in non-
mammalian species. For instance, the cDNA of the calcium-
regulating hormone stanniocalcin has been initially cloned in
teleost fish (Butkus et al., 1987) and the human ortholog has
been identified only a decade later (Olsen et al., 1996; Chang
et al., 1998). Similarly, the cDNA of the hypertensive peptide
urotensin II (UII) has been first characterized in frog, and
has been subsequently used to identify the human UII cDNA
sequence (Coulouarn et al., 1998). Theoretically, invertebrate
genomic sequences could also be exploited for the identification
of vertebrate neuropeptide cDNAs (Elphick et al., 2018). The
comparative approach has also been used successfully at the
peptidic level. Thus, melanin-concentrating hormone (MCH)
which has been initially identified in fish as a pituitary hormone
(Kawauchi et al., 1983) was subsequently sequenced in a rat
hypothalamic extract (Vaughan et al., 1989) before its cDNA
was finally cloned in rat (Nahon et al., 1989) and human
(Presse et al., 1990).
The detection of possible alternative splicing events may also
lead to the discovery of novel regulatory peptides. This was
the case with the calcitonin primary transcript that, through
tissue-specific processing, can give rise to two distinct mRNAs
FIGURE 5 | Representation of the various steps of peptidomic studies. Each
step can be adapted to the specificity of the peptide, the complexity of the
matrix and the information needed (e.g., identification, quantification). HPLC:
high pressure liquid chromatography.
Frontiers in Neuroscience | www.frontiersin.org 6 September 2019 | Volume 13 | Article 948
fnins-13-00948 September 14, 2019 Time: 12:26 # 7
Corbière et al. Strategies for the Identification of Bioactive Neuropeptides
i.e., calcitonin mRNA in thyroidal C cells and calcitonin gene-
related peptide (CGRP) mRNA in neuronal cells (Amara et al.,
1982; Rosenfeld et al., 1983). CGRP has thus been originally
identified as an alternative splicing product of the calcitonin gene.
Genome sequencing of representative species of the different
phyla has allowed the development of libraries containing almost
all the genomic sequences of these species. However, the lack
of gene annotations has made it necessary to create powerful
computer tools to screen these libraries for the identification of
novel neuropeptides. The developed softwares employ various
strategies. First, sequence alignments can be used to compare
non-annotated genes in one species with genes encoding
neuropeptides in another species (Siepel et al., 2005). Thus,
the genes that are conserved during evolution can be identified
and are likely to exert an important function (Sonmez et al.,
2009). Then, screening of cDNA libraries can identify sequences
having common patterns with known neuropeptide families,
such as the RFamide motif (Nathoo et al., 2001). Finally, it is
possible to rely on the characteristics of neuropeptide precursors
to screen genomic libraries for candidate sequences (Hewes
and Taghert, 2001). These approaches use mathematical models
like the Markov model, assigning a score to the sequences
according to their correspondence with each of the criteria. It
is then necessary to verify the expression of these sequences in
neuronal cells and to look for an activity of the putative peptide.
Nevertheless, in silico analysis can lead to a large number of
predicted peptide candidates, which may require the synthesis of
an important peptide library for subsequent biological screening
(Liu et al., 2008; Shemesh et al., 2008; Kliger, 2010). But some
methods can help to reduce this number of candidates by
using gene expression mapping to create peptide-receptor pairs
(Williams et al., 2017).
It should be noted that these genomic techniques of
identification of neuropeptides are progressively being
supplanted by new and more efficient approaches. In particular,
the evolution of mass spectrometry techniques has allowed the
development of global peptidomic approaches for the discovery
of novel biologically active peptides.
IDENTIFICATION USING PEPTIDOMIC
APPROACHES
The term peptidomic appeared for the first time in 2001 in a study
using mass spectrometry to develop a peptide profile in locusts
(Clynen et al., 2001). Peptidomic methods (Figure 3) require a
smaller amount of starting material and a shorter analysis time by
reducing the successive purification steps. In addition, they make
it possible to obtain more information on the candidate peptides,
such as their sequence or the presence of post-translational
modifications. Peptidomic studies are conventionally carried out
in 4 steps, namely (i) peptides extraction, (ii) separation, (iii)
detection and (iiii) identification and quantification (Figure 5).
The preservation of the peptides in their native state is crucial
for peptidomic studies and must begin as soon as the sample
is collected, to avoid the breakdown of proteins into peptides
(false positives) or the degradation of the bioactive peptides
(false negatives). Protection of the samples can be achieved
FIGURE 6 | Correlation between the expression level of various peptides and the mechanisms occurring during cerebellar cortex development. (A) Variation of five
peptide concentrations during cerebellar development. (B) Temporal evolution of the cellular processes involved in cerebellar development, i.e., proliferation,
migration, differentiation and cell death. Peptide concentrations are high during the developmental processes on which they act. P: postnatal day. PACAP: pituitary
adenylate cyclase-activating polypeptide.
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by heat denaturation of the proteolytic enzymes, acidification
and/or addition of protease inhibitors. This can be done manually
or using specific equipment such as the heat stabilization
system Denator R©. The extraction step has been refined and
becomes more accessible and reproducible by the outbreak of
commercial extraction tools. This step may include the use of
centrifugal filters to remove larger proteins. The cut-off threshold
conventionally used in peptidomics is 10 kDa, to get rid of
proteins with a size greater than one hundred amino acids. The
purification procedure is complemented using chromatography
devices such as ZipTips R© or Sep-Pak R© to desalt, concentrate
and purify samples.
The separation step, carried out upstream of the mass
spectrometer, has been improved to allow the analysis of complex
mixtures. Indeed, while it is possible to identify peptides via
direct analysis of the sample by mass spectrometry, the presence
of peptides and proteins of different molecular weight and
variable concentrations in a complex matrix necessitates to
include one or more separation steps upstream of the analyzer.
This limitation can be circumvented by coupling the mass
spectrometer to a separation method allowing the successive
analysis of the various compounds of the sample by mass
spectrometry. High performance liquid chromatography (HPLC)
makes it possible to separate the peptides according to their
hydrophobicity, polarity and/or size. The miniaturization of
the columns (nanoHPLC) and the increase of the pressure
(ultraHPLC), permit to increase the system sensitivity and
resolution, and thus to improve the analyte separation. These
ameliorations contribute to significantly reduce the amount
of samples needed.
Peptide identification and quantification by mass spectro-
metry has also been considerably improved in recent years,
particularly with the implementation in the proteomic platforms
of devices such as high-resolution accurate-mass Orbitrap
mass spectrometers which surpass the MALDI-TOF MS
systems. The sensitivity level, acquisition rate, and range of
analyzable masses have steadily increased through progress
of ionization, ion trapping, and fragmentation (Eliuk and
Makarov, 2015). In particular, the expansion of peptidomic
techniques allowing the accumulation of information on
peptide sequences and post-translational modifications has been
facilitated by combination of fragmentation modes such as CID
(Collision Induced Dissociation), HCD (Higher-Energy Collision
Induced Dissociation) and ETD (Electron Transfer Dissociation)
(Hayakawa et al., 2013). Peptide identification and quantification
has also been made easier with advances in computer science.
Indeed, the increase in the amount of data generated, that can
reach for each experiment several tens of gigabytes, implies
the development of bioinformatic databases and algorithms. In
particular, data analysis is now facilitated by the development
of powerful softwares to perform label-free quantitation (such
as Progenesis), or database queries (such as Spectrum Mill or
Mascot; Martens et al., 2005).
If peptidomic techniques were initially set up and still
contribute to identify novel neuropeptides de novo, quantitative
peptide profiling by mass spectrometry (also called differential
peptidomics) is now used to screen and quantify already
characterized peptides in tissues where they were not known
to be present and in different conditions. Such an approach
was used to characterize peptides with daily regulation in
the rat suprachiasmatic nucleus and led to the discovery that
the peptide VGRPEWWMDYQ (AA 219–229), derived from
proenkephalin A, is significantly increased at night-time (Lee
et al., 2013). Still in the brain but during development, peptides
acting on the ontogenesis of the cerebellar cortex (the external
part of the cerebellum) often exhibit a specific pattern of
expression with, in rodents, high expression over the first
2 postnatal weeks, and a decline at adulthood (Figure 6;
Inagaki et al., 1989; Villar et al., 1989; Malagon et al., 1993;
Tatsuno et al., 1994; Kaddour et al., 2013; Komuro and
Fahrion, 2013). Based on this observation, it was possible
to identify additional peptides exhibiting such a bell-shape
expression profile (Corbière et al., 2018). Using a neuropeptide
database, 33 peptides were identified in the cerebellum by
mass spectrometry, among which 4 had a high expression
level during development, which then decreased at adulthood.
Further studies conducted on one of them, i.e., nociceptin,
confirmed that not only the peptide but also the expression
FIGURE 7 | Representation of the workflow used to filter the peptides
identified by de novo sequencing. Sequences with a PEAKS score higher than
70 were compared to UniProt/SwissProt database in order to exclude
peptides originating from already known precursors. Remaining sequences
were filtered by occurrence among samples (>7/10) and regulation during
development (>2). This workflow led to the selection of 11 sequences which
correspond to putative peptides.
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of its precursor gene and of its receptor are regulated during
development. As the developing cerebellar cortex is composed
of a dozen of cell types spread in 4 different well defined
layers, an attempt was conducted to identify nociceptin by a
MALDI-imaging approach. Although 8 compounds differentially
expressed during cerebellar development could be detected
through this approach, no peptide with an m/z corresponding
to nociceptin could be unequivocally identified. Two peptides
whose expression increased with cerebellar maturation may
correspond to cerebellin-1 and [des-Ser1]-cerebellin but the
measurement accuracy and the lack of fragmentation data show
the limits of this approach (Belov et al., 2017). In fact, even if
there are many developments around MALDI imaging, to date,
only few bioactive peptides have been clearly identified through
this approach (Ljungdahl et al., 2011; Hanrieder et al., 2012; Sui
et al., 2017; Huber et al., 2018). To circumvent the problem, laser
microdissection of the tissue coupled with real time PCR analysis
was used to determine that both nociceptin and its receptor
genes were mostly expressed in the internal granular layer of
the cerebellar cortex, which mainly contains granule neurons.
Subsequent functional studies showed that nociceptin exerts a
neurotrophic effect on those granule neurons by increasing their
survival and promoting their differentiation (Corbière et al.,
2018; Figure 7). In an attempt to obtain information regarding
cell specific peptide content, single cell neuropeptide profiling is
a new challenge which has started to be developed (Jiménez et al.,
2006; Neupert et al., 2012; Do et al., 2018).
DE NOVO IDENTIFICATION
To identify unknown peptides, de novo peptide sequencing
of experimental data obtained by mass spectrometry can be
carried out using softwares such as PEAKS. Nevertheless, some
filters have to be applied to reduce the number of obtained
sequences. A first step can be to eliminate all the sequences
already present in SwissProt and/or UniProt databases coding
for already known proteins and then to only retain sequences
expressed recurrently and potentially regulated by a treatment,
a disease or a developmental process. This allows the selection
of several candidate peptides that are potentially bioactive in
order to reverse-transcribe their sequence to identify the gene
from which they are derived. Nevertheless, it remains to be
determined whether some of these sequences can correspond
to bioactive peptides. This can be achieved by looking at some
selection criteria such as the presence of a sequence coding
for a signal peptide upstream of the peptide of interest, the
existence of basic doublets at the N- and C-terminal ends which
may correspond to cleavage sites by PCs, and evolutionary
conservation. If the peptide is under certain conditions regulated,
it can be looked at the regulation of its gene expression and,
finally, possible functions should be investigated. This complex
approach, which requires support from bioinformatics teams,
has led to the identification of Neuroendocrine regulatory
peptides (NERP-3; Sasaki et al., 2009) and other peptides derived
from the VGF sequence (Sasaki et al., 2010). New methods of
identification are also used to reduce the search space for spectral
matching to improve the discrimination between correct peptide
identification and false hit, and thus decrease the number of
sequences (Hayakawa et al., 2013). Proteogenomics approaches
are now also emerging to identify functional micropeptides
produced from sORFs within cells of diverse species (Yeasmin
et al., 2018). This approach often leads to a large number
of peptide candidates that can nowadays be synthesized with
dedicated robotic systems such as the Apex 396HT R© Peptide
Library Synthesizer.
The strategies developed in order to identify novel bioactive
peptides have evolved considerably during the past decades. The
successful but laborious pioneer tissue purifications combined
to biological tests or immunoassays, that were rewarded by
the attribution of several Nobel Prizes (Du Vigneaud, 1954;
Guillemin, 1977; Schally, 1977; Yalow, 1977), are now supplanted
by reverse pharmacology and peptidomic approaches which
have already led to the discovery of several bioactive peptides.
Owing to the raising interest of the pharmaceutical industry for
peptide-based drugs (Fosgerau and Hoffmann, 2015; Henninot
et al., 2018), the search of novel biologically active peptides
is currently a very active domain. Rapid developments in
bioinformatics, combined with powerful analytical methods and
highly sophisticated mass spectrometers, should allow to de-
orphanize the dozens of still orphan peptide-targeted GPCRs
in vertebrates. These novel bioactive peptides will undoubtedly
contribute to the rational design of innovative compounds either
peptidergic analogs or small molecule-base drugs.
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